Medicinova MN-166-ALS-2301, COMBAT-ALS: Phase 2b/3, placebo-controlled trial of MN-166/Ibudilast in participants with Amylotrophic Lateral Sclerosis (ALS)
C
Cynthia Bodkin, MD
Primary Investigator
Administratively Closed
18 years - 80 years
All
Phase
2/3
10 participants needed
2 Locations
Brief description of study
Who is Eligible
- Ages 18-80
- Diagnosis of ALS with symptoms starting less than 18 months ago
- Able to swallow medication capsules
- No history of cancer within last 5 years
- No use of tracheostomy or almost continuous ventilator support
What is Invovled
- In-person appointments at the IUH Neuroscience Center
- Participants will take Ibudilast capsules twice daily for approximately 18 months of participation. Some telephone appointments available.
Compensation
- Compensation available via payment card for each completed appointment
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Amylotrophic Lateral Sclerosis,ALS
-
Age: 18 years - 80 years
-
Gender: All
Updated on
27 Aug 2025.
Study ID: NEUR-MEDICINOVA-ALS-2301, MRI-MEDTRONIC-MARIASH-PS, 2001659563
